takeaway discuss manag
discuss potenti near-term impact manag key
takeaway relat risk mitig plan place
registr monotherapi arm krystal still track report
month durabl data nsclc patient year-end combin arm
antibodi potenti subject reduc patient flow
iv infus sitravatinib may impact reduc patient enrol
sapphir studi recent discuss suggest registr
data potenti nda file base view impact
lower sale estim sitravatinib drive new price
target maintain outperform
interview two oncolog expert dr curti chong stanford dr ryan
corcoran harvard indic oral kra inhibitor remain top
prioriti among clinic trialist base potenti signific therapeut benefit
refractori patient oral administr allow shipment directli patient
without dose interrupt seen trial iv drug blood draw safeti data
collect local
put risk mitig plan place allow enrol krystal
continu track origin timelin despit enrol
without person contact enabl archiv biopsi sampl confirm
mutat subset nsclc patient monotherapi
alreadi enrol durabl data expect medic meet
registr dataset monotherapi nsclc remain track
patient demonstr least orr six month durabl
sometim accord expect recent fda guidanc allow
relat provis maintain continu integr
studi
understand initi new studi site new studi protocol
combin potenti subject relat delay exampl
studi involv co-administr antibodi may subject reduc
patient access iv infus disrupt could potenti impact time
combo sitravatinib studi
adjust model base expect fulli enrol
dec readout potenti registr dataset least six month
one year ahead kra monotherapi late line nsclc
updat model lead later launch assumpt slightli lower peak sale
estim drive new prior
year price histori
mirati clinical-stag
genet defin tumor
analyst certif import disclosur see disclosur
model launch nsclc sitravatinib nivolumab
model potenti kra launch
estim sell price experiment product
low mirati gain fda approv indic
model market penetr rapid
estim would signific upsid estim
anticip mirati commerci development-stag
drug sitravatinib nsclc renal cell kra inhibitor
believ candid
potenti well differenti product profil especi
target kra difficult-to-drug
updat sitravatinib nivo data bladder variou
orr interim data sitravatinib nsclc studi
os data sitravatinib nsclc studi
acknowledg possibl signific downsid
estim due inher risk drug develop
worst case mirati stock could littl valu
valu use dcf valuat methodolog price target base dcf valuat wacc
residu growth rate base patent expir
biggest risk price target possibl product candid gain fda approv therefor becom
commerci product gain approv risk remain includ potenti inabl get favor price patient behavior
physician adopt product patent protect structur chang healthcar market
probabl success
probabl success
probabl success
probabl success
collabor revenu mileston
good
research devleop
adjust research develop non-gaap
share-bas compens
total share-bas compenst
gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compenst
total share-bas compens exclud non-gaap
total non-oper income/ expens
earn tax loss
equival
